CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 102 enrolled
Drug / intervention
MT-7117 low dose +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03520036
NCT03520036Phase 2Completed
CompareCT.gov

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Subjects With Erythropoietic Protoporphyria

Tanabe Pharma America, Inc.·interventional·Posted May 9, 2018·Updated Dec 31, 2025

In Brief

A Phase 2 clinical trial evaluating MT-7117 low dose, MT-7117 high dose, and 1 other intervention for Erythropoietic Protoporphyria (EPP). Completed, enrolled 102 participants across 9 sites.

Detailed Summary

The purpose of this study is to investigate the efficacy and safety of MT-7117 on sunlight exposure duration without symptoms and tolerance in subjects with EPP.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsErythropoietic Protoporphyria (EPP)
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedMay 9, 2018
Enrollment StartJul 5, 2018
Primary CompletionSep 28, 2019
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 8.1 years ago

Interventions

MT-7117 low dosedrug

MT-7117 low dose QD, oral, 16 weeks

MT-7117 high dosedrug

MT-7117 high dose QD, oral, 16 weeks

Placebodrug

Placebo QD, oral, 16 weeks